These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26317309)

  • 1. BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells.
    Uguen A; Guéguen P; Talagas M; Costa S; De Braekeleer M; Marcorelles P
    Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):e14-5. PubMed ID: 26317309
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma.
    Chiappetta C; Proietti I; Soccodato V; Puggioni C; Zaralli R; Pacini L; Porta N; Skroza N; Petrozza V; Potenza C; Della Rocca C; Di Cristofano C
    Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):172-7. PubMed ID: 24710085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 4. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
    Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
    [No Abstract]   [Full Text] [Related]  

  • 5. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjunctival melanomas harbor BRAF and NRAS mutations--response.
    Griewank KG; Westekemper H; Schilling B; Livingstone E; Schimming T; Sucker A; Hillen U; Steuhl KP; Zimmer L; Schadendorf D
    Clin Cancer Res; 2013 Nov; 19(22):6331-2. PubMed ID: 24170549
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of BRAF and NRAS mutations in fast-growing melanomas.
    Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D
    Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684
    [No Abstract]   [Full Text] [Related]  

  • 8. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
    Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
    Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.
    Gouillon L; Perier-Muzet M; Amini-Adle M; Poulalhon N; Debarbieux S; Boespflug A; Balme B; Depaepe L; Harou O; Lopez J; Bringuier PP; Ferraro-Peyret C; Maucort-Boulch D; Robinson P; Thomas L; Dalle S
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e57-e59. PubMed ID: 31442328
    [No Abstract]   [Full Text] [Related]  

  • 17. Conjunctival melanomas harbor BRAF and NRAS mutations--Letter.
    Weber JL; Smalley KS; Sondak VK; Gibney GT
    Clin Cancer Res; 2013 Nov; 19(22):6329-30. PubMed ID: 24166902
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
    Mangana J; Cheng PF; Schindler K; Weide B; Held U; Frauchiger AL; Romano E; Kähler KC; Rozati S; Rechsteiner M; Moch H; Michielin O; Garbe C; Hauschild A; Hoeller C; Dummer R; Goldinger SM
    PLoS One; 2015; 10(10):e0139438. PubMed ID: 26426340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
    Hsieh R; Nico MM; Camillo CM; Oliveira KK; Sangueza M; Lourenço SV
    Am J Dermatopathol; 2017 Feb; 39(2):104-110. PubMed ID: 28134726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.